BTIG resumed coverage of Accelerate Diagnostics (AXDX) with a Buy rating and $14 price target The company’s position as the leading middle-market B2B invoice and payments company should drive a long, durable growth trajectory for the next several years, the analyst tells investors in a research note. AvidXChange is currently growing below its medium-term target and there are “points for bears to pick at”, but BTIG believes that the company has built a moat around the middle-market verticals, which are still in the very early innings of converting their invoice and payments capabilities to a digital and automated solution, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXDX: